➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
McKinsey
Dow
Colorcon
Moodys

Last Updated: December 4, 2020

DrugPatentWatch Database Preview

Litigation Details for Staley v. Gilead Sciences, Inc. (N.D. Cal. 2019)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Staley v. Gilead Sciences, Inc. (N.D. Cal. 2019)

Docket   Start Trial Date Filed 2019-05-14
Court District Court, N.D. California Date Terminated
Cause 15:1 Antitrust Litigation Assigned To Edward Milton Chen
Jury Demand Both Referred To Laurel D. Beeler
Parties AKROS PHARMA INC.; JAPAN TOBACCO INTERNATIONAL U.S.A. INC; STEVE FULLER
Patents 10,441,543; 6,642,245; 6,703,396; 7,390,791; 7,803,788; 7,884,196; 8,206,737; 8,236,306; 8,293,923; 8,598,185; 8,609,354; 8,754,065; 8,841,310; 9,018,192; 9,198,954; 9,296,769; 9,410,954; 9,545,414
Attorneys Ashley Lynn Shively; Brianna Ricque Howard; Jeffrey L. Kodroff; Jerome W Hoffman; John Palmer Kern; Neal N. Beaton; Thomas Joonyul Yoo
Firms Holland & Knight; Holland and Knight LLP; Holland and Knight, LLP; Nussbaum Law Group, P.C.
Link to Docket External link to docket
Small Molecule Drugs cited in Staley v. Gilead Sciences, Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Staley v. Gilead Sciences, Inc.

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Staley v. Gilead Sciences, Inc. (N.D. Cal. 2019)

Date Filed Document No. Description Snippet Link To Document
2019-05-14 1 Complaint Paragraph IV certification 19 as to Gilead’s patents 6,642,245 and 6,703,396 that claim the FTC composition…listed patent(s) and/or the patent is invalid and 10 unenforceable. Simply by listing the patents in the…ANDA applicant for patent 15 infringement. If the brand manufacturer brings a patent infringement action…legitimate patent protection or ferret out invalid, unenforceable, or 16 narrow drug patents. 17 18 …even after the 15 patents on them expired. 16 91. Gilead’s patents on TDF, FTC, and TDF External link to document
2019-08-22 118 Complaint Paragraph IV certification 2 as to Gilead’s patents 6,642,245 and 6,703,396 that claim the FTC composition…listed patent(s) and/or the patent is invalid and 23 unenforceable. Simply by listing the patents in the…ANDA applicant for patent 28 infringement. If the brand manufacturer brings a patent infringement action…applied for patents that 26 claim the formulation of TAF with FTC. See, e.g., United States Patent Application…Gilead’s patents protecting TAF can be divided into two groups: 7 Group Patent Patent External link to document
2020-04-21 304 Amended Complaint Paragraph IV certification as to Gilead’s patents 6,642,245 and 6,703,396 that claim the FTC enantiomer…Gilead’s principal patents on TAF are Patent No. 7,390,791 (the ’791 Patent) and Patent 15 No. 7,803,…from the Patent and Trademark Office 4 (“PTO”) a patent-term extension on its principal patent on TAF…listed patent(s) and/or the patent is invalid and 11 unenforceable. Simply by listing the patents in the…the patent has issued. 35 U.S.C. § 156(c). The ’791 Patent issued in June 2008 and the ’788 Patent External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Medtronic
Baxter
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.